Joan Manel Mañé
Highly Influential Citations2
Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage publications (all current information on this profile has been aggregated automatically from publisher and metadata sources).
INTRODUCTION In an attempt to increase the dose intensity of cisplatin and gemcitabine given to patients with stage IIIB or IV nonsmall cell lung cancer without increasing toxicity, we have studied a… Continue Reading
16505 Background: Dx and Cap are useful drugs in head and neck cancer. Our purpose was to establish the efficacy and safety of this combination in non selected patients (pts) with advanced or metas...
308 Background: Pancreatic and biliary tree ADC represent poor prognostic tumors. Gemcitabine is usually considered the first- line chemotherapy and after that no standard treatment has been… Continue Reading
Aims and Background The objective of the study was to evaluate the efficacy of combined chemoradiation in patients with newly diagnosed glioblastoma multiforme. The main end points were time to… Continue Reading
15625 Background: Patients (pts) with advanced pancreatic (P), biliary (B) and gallbladder (GB) adenocarcinoma have a poor prognosis. Gemcitabine (G) is the standard treatment for patients with APB...
Clinical systemic amyloidosis has been rarely described in patients with lung cancer. A new case of such an association is described with a review of the literature and a discussion about the… Continue Reading
4187 Background: Combination chemotherapy improves overall survival and quality of life in metastatic gastric cancer. Capecitabine (CAP), a new oral fluoropyrimidine has shown equivalent activity, ...
Aims and background Gemcitabine is an effective agent in pancreatic adenocarcinoma. Fixed-dose-rate gemcitabine has an interesting biological and clinical rationale, with successful results in… Continue Reading
304 Background: G (30-minute infusion) plus E improves survival in patients with APC compared with G alone. In a recent phase III trial, G-FDR showed a trend to better OS compared with standard G… Continue Reading
e13000 Background: Glioblastoma multiforme constitutes the most common and malignant form of primary brain tumor. Median survival for recurrent disease is 3-9 months. Combining bevacizumab with… Continue Reading